Applied BioCode Aktsia

Applied BioCode ROE

ROE (Return on Equity) ettevõttest Applied BioCode (6598.TW) seisuga 9. aug 2026 on −31,28 %. Eelmisel aastal oli ROE (Return on Equity) −29,68 % — muutus 5,40% (madalam).

ROE

−31,28 %

YoY

5,40%

Viimati uuendatud:

Aastal 2026 oli Applied BioCode omakapitali tootlus (ROE) −31,28 %, mis on 5,40% suurem võrreldes −29,68 % ROE-ga eelmisel aastal.
Access this data via the Eulerpool API

Applied BioCode Aktsiate analüüs

Mida Applied BioCode teeb? Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice. Applied BioCode on üks populaarsemaid ettevõtteid Eulpoolist.

ROE detailides

Omakapitali tootluse (ROE) dešifreerimine ettevõttes Applied BioCode

Ettevõtte Applied BioCode omakapitali tootlus (ROE) on põhinäitaja, mis hindab ettevõtte rentaablust omakapitali suhtes. ROE, mis arvutatakse netokasumi jagamisel aktsionäride omakapitaliga, illustreerib, kui tõhusalt ettevõte genereerib kasumeid aktsionäride investeeringutelt. Kõrgem ROE näitab suurenenud efektiivsust ja rentaablust.

Aasta-aasta võrdlus

Ettevõtte Applied BioCode ROE analüüs aasta-aasta võrdluses aitab jälgida rentaablustrende ja finantssooritust. ROE tõus näitab suurenevat rentaablust ja väärtuse loomist aktsionäridele, samas kui ROE vähenemine võib osutada probleemidele kasumite genereerimisel või omakapitali haldamisel.

Mõju investeeringutele

Ettevõtte Applied BioCode ROE on investorite jaoks oluline, sest see aitab hinnata ettevõtte rentaablust, efektiivsust ja investeerimisatraktiivsust. Tugev ROE näitab ettevõtte võimet muuta omakapitali investeeringud kasumiks, suurendades sellega selle atraktiivsust potentsiaalsetele ja praegustele investoritele.

ROE kõikumiste tõlgendamine

Muutused ettevõtte Applied BioCode ROEs võivad tuleneda netokasumi, omakapitali või mõlema kõikumistest. Neid kõikumisi uuritakse, et hinnata juhtkonna efektiivsust, finantsstrateegiaid ning nendega seotud riske ja võimalusi, aidates investoritel teha informeeritud otsuseid.

Sageli esitatud küsimused Applied BioCode aktsia kohta

Applied BioCode ROE (Return on Equity) on 2026. aastal −31,28 %.

ROE (Return on Equity) ettevõttest Applied BioCode muutus −29,68 % -st −31,28 % -ks, mis vastab 5,40% muutusele. Väärtus on madalam kui eelmisel aastal.

Eulpoolist leiate ROE (Return on Equity) Applied BioCode täieliku ajaloolise arengu alates 2006. aastast – koos aastate väärtustega, graafikutega ja üksikasjalike analüüsidega.

Hea väärtus varieerub tööstuse ja ettevõtte arenguetapi järgi. Eulpoolis saate ROE (Return on Equity) Applied BioCode võrrelda sektori konkurentidega ja tööstuse keskmisega, et hinnata selle atraktiivsust.

ROE (Return on Equity) hindamiseks on oluline võrrelda seda sama tööstuse ja sektori ettevõtetega. Eulpoolis leiate ROE (Return on Equity) jaoks otsesed tööstusesisesed võrdlused.

Access this data via the Eulerpool API

Kasumlikkus — Applied BioCode

Kõik finantsnäitajad — Applied BioCode